Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Consistent long-term performance driving confidence for future Novartis delivers solid Q3 results, with strong performance of Innovative Medicines Raised peak sales guidance for Cosentyx® and EntrestoⓇ We remain confident in the strength of our pipeline and launch brands to fuel the growth of our company in the mid to longer term Announced strategic review of Sandoz to maximize shareholder value 46 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation